Xtalks to Host Webinar on AAV Therapy Potency Assurance
Xtalks will host a free webinar focusing on how next-generation sequencing (NGS) can support total potency assurance for adeno-associated virus (AAV) therapies.
Technology company Xtalks is hosting a webinar to discuss the role of next-generation sequencing (NGS) in ensuring total potency assurance for adeno-associated virus (AAV) therapies.
The session will explore how NGS-based testing can assess sequence purity and quantify sequence variants or vector subpopulations. The goal is to enhance the quality and reliability of AAV-based treatments.
The featured speaker will present methods for verifying the consistency of AAV therapy production processes and ensuring the final product meets established quality standards. This is critical for the clinical application of biologics.
The webinar is intended for biotechnology professionals, researchers, and quality assurance experts involved in gene therapy development. Attendees will gain insights into the latest analytical techniques and their practical implementation.